G12D
· 3 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | G12D | “Using steered molecular simulations we quantified the binding free energies (ΔGbind) of GDP to wild-type (WT) KRas and its key oncogenic mutants G12C, G12D, G12R, and G12V, with and without MRTX1133 a potential inhibitor of the KRas G12D variant.” | 0.82 | literature_variant_regex_v2 |
| variant | G12D | “This study employs a comprehensive approach combining protein retrieval, sequence alignment, and molecular dynamics simulations to investigate the structural dynamics and stability of wild-type KRas and its mutated variants (G12C, G12D, G12V, and G13D).” | 0.82 | literature_variant_regex_v2 |
| variant | G12D | “MRTX1133's robust interaction with Tyr64 and disruption of Tyr96-Tyr71-Arg68 network showcase its ability to mitigate the effects of the G12D mutation.” | 0.82 | literature_variant_regex_v2 |